Researchers at Karolinska Institutet in Sweden identified an experimental antidiabetic compound that can protect pancreatic ß cells from “overloading” under the metabolic stresses of diabetes, and so prevent high blood glucose and the progression of diabetes in different mouse models. When tested in human organoids, the HIF-1α inhibitor, PX-478 —which has already been evaluated in Phase I trials against cancer—showed preliminary promise as an antidiabetic therapeutic agent.